Germline intragenic mutations in PTEN, a tumor suppressor gene located on 10q23.3 and encoding a lipid and protein-tyrosine phosphatase, are associated with 80% of patients with Cowden syndrome (CS) characterized by multiple hamartomas and an increased risk of breast, thyroid, and endometrial cancers, and 60% of patients with Bannayan-Riley-Ruvalcaba syndrome (BRRS) characterized by macrocephaly, lipomatosis, and speckled penis. Despite extensive PCR-based PTEN mutation analysis in these two syndromes, the underlying genetic causes remain to be determined in a considerable proportion of classic CS and/or BRRS without a PCRdetectable PTEN mutation. Because CS is believed to be without locus heterogeneity, we hypothesized that gross gene deletions and mutations in the PTEN promoter might alternatively account for a subset of apparently mutation-negative CS and/or BRRS 
Introduction
Cowden syndrome (CS, OMIM 158350 ) is an autosomal dominant disorder that is characterized by multiple hamartomas affecting derivatives of all three germ layers and by an increased risk of breast, thyroid, and endometrial neoplasia (Eng 2000) .
PTEN/MMAC1/TEP1 (OMIM 601728), a tumor suppressor gene located at 10q23.3, encodes a dual-specificity phosphatase which functions as a major 3'-phosphatase and antagonizes the phosphoinositol-3-kinase (PI3K)/Akt pro-apoptotic pathway (Nelen et al. 1996; Li and Sun 1997; Steck et al. 1997; Maehama and Dixon 1998; Stambolic et al. 1998) . Via this and PI3K/Akt-independent pathways, proper PTEN signaling leads to G1 cell cycle arrest and/or apoptosis (Furnari et al. 1998; Li and Sun 1998; Stambolic et al. 1998; Weng et al. 1999; Weng et al. 2001a; Weng et al. 2001b; Weng et al. 2001c; Weng et al. 2001d; Weng et al. 2002) . When ascertained strictly by the International Cowden Consortium Operational Diagnostic
Criteria, approximately 80% of CS have been found to carry germline mutations in PTEN Marsh et al. 1998 ). In addition, germline mutations of PTEN have been found in 60% of individuals with Bannayan-Riley-Ruvalcaba syndrome (BRRS, OMIM 153480) Marsh et al. 1998; Marsh et al. 1999 ).
Subsequently, the clinical spectrum of disorders that are associated with germline PTEN mutations has expanded to include seemingly disparate syndromes, such as Proteus syndrome (OMIM 176920), Proteus-like syndromes, and VATER association with macrocephaly (Zhou et al. 2000b; Reardon et al. 2001; Zhou et al. 2001; Smith et al. 2002) .
Despite extensive PTEN mutation analysis in both the research and clinical setting in the two autosomal dominant hamartomatous syndromes, CS and BRRS, the underlying genetic causes remain undetermined in 20% and 40%, respectively, of individuals with classic CS and/or BRRS, in whom no mutations have been detected by conventional mutation detection techniques, ie, PCR-based single-strand conformation polymorphism analysis (SSCP), denaturing gradient gel electrophoresis (DGGE) and direct DNA sequencing [reviewed by (Waite and Eng 2002) ]. Because CS is believed to be without genetic heterogeneity (Nelen et al. 1996) , we hypothesized that apparently PTEN mutation negative CS and BRRS may be attributed to large gene rearrangements and deletions, which cannot be detected by PCR-based mutation detection strategies, and promoter mutations. To test our hypotheses, therefore, we used a combination of real-time quantitative multiplex PCR analysis, fluorescent-based semi-quantitative PCR assays and microsatellite analyses to define and characterize PTEN and regional deletions in 122 CS and BRRS probands previously found not to have intragenic PTEN mutations. Further, deletion negative samples were subjected to sequence analysis of the promoter region of PTEN. Finally, we biochemically characterized the potential pathogenicity of the deletion and promoter mutations.
Patients, Materials and Methods

Subjects and DNA Extraction
After informed consent, peripheral blood was obtained from 122 unrelated individuals, who were diagnosed with CS according to the diagnostic criteria set by the International Cowden Consortium (Eng 2000) and BRRS by the original clinical definition (Gorlin et al. 1992) . In addition, these subjects were found to have no germline mutations in the PTEN coding region, exon-intron boundaries or flanking intronic regions by DGGE and direct sequencing, were analyzed for gene deletions, duplications and promoter mutations. Overall, 96 (79%) had classic CS, and 26 (21%) had BRRS. Clinical phenotypic details including organ-specific cancers and benign processes and PHTS-related features [detailed by , were available for all individuals and their families. Normal controls comprised commercially available pooled human genomic DNA (Promega, Madison, WI) and 186 healthy Caucasian blood donors. Germline DNA from peripheral blood leukocytes from cases and controls were extracted using standard techniques (Miller et al. 1988 ). In addition, remaining leukocytes from 32 normal controls and a subset of cases were EBV-transformed for lymphoblastoid cultures (Fukushima et al. 1992) .
Multiplex Real-Time Quantitative PCR
The real-time quantitative PCR and analysis were carried out using the ABI 7700 Sequence Detector System (ABI/Perkin Elmer, Foster City, CA) as previously described (Sieber et al. 2002) . Real-time quantitative PCR assay determines gene dosage (or copy number) by monitoring PCR amplification in real-time and using the 5'-nuclease activity of Taq DNA polymerase. PTEN exons 1 and 5 were chosen as targets for the real-time quantitative PCR assay, while the remaining exons were analyzed by using a fluorescent-based semi-quantitative multiplex PCR approach as detailed below. Exon 8 of human RET, a proto-oncogene located at 10q11.2 which is not deleted or amplified in the germ-line of CS and/or BRRS patients, was chosen as internal control. The primers and probes were designed by using PRIMER EXPRESS software (Applied Biosystems). The PTEN exon 1 and exon 5 probes were labeled at the 5' ends with the reporter dye FAM and at the 3' end with the MGBNF quencher.
The RET exon 8 probe was labeled at the 5' end with reporter dye VIC and at the 3' end with the MGBNF quencher. Primer and probe sequences are listed in Table 1 . 
Semi-quantitative Fluorescent Multiplex PCR
Short fragments (<300 bp) of PTEN exons 2, 3, 4, 6, 7, 8, 9 and RET exon 8, as an internal control, were simultaneously PCR amplified, using 6-FAM labeled primers (Table 1) . Three multiplex PCRs were necessary to cover all of the exons. 
Microsatellite and SNP Analysis
Genotypes were determined by using nine polymorphic marker loci as described previously (Marsh et al. 1999; Zhou et al. 2000a) 
PTEN Promoter Mutation Analysis
Primers were designed to amplify the full length of the PTEN promoter region between -1344 bp and -745 bp upstream of the translation start codon (Sheng et al. 2002) (Table 1) and a model 377 automated sequencer (Applied Biosystems).
Cellular Protein Extraction
Lymphoblast cell lines were generated by immortialization of patient and control lymphocytes with Cylclosporin-A, and Epstein-Barr virus. Cells were maintained in RPMI containing 20% FBS and passaged as needed. Approximately 10 million cells were pelleted by centrifugation (800 x g, 10 min, 4˚C), the resulting pellet was then washed twice with ice cold PBS, followed by centrifugation and resuspended in mammalian lysis buffer (Pierce, Rockford, IL) containing 500 mM PMSF, 5 µg/ml each of leupeptin, aprotinin, and pepstatin, 2 mM sodium orthovanadate, 50 mM NaF and 10 mM β−glycerophosphonate. Insoluble cellular material was removed by centrifugation at 4˚C. Protein concentration was determined by the bicinchoninic acid method with bovine serum albumin as a standard (Smith et al. 1985) .
Western Blot Analysis
Proteins (30 µg) were separated by 10% SDS-PAGE using the Laemelli method (Laemmli 1970) , after electrophoresis, proteins were electrophoretically transferred to nitrocellulose (Towbin et al. 1979) . Nitrocellulose blots were blocked by incubation for 1 hr in 5% milk in TBS-T (10 mM Tris pH=7.0, 100 mM NaCl and 0.1% Tween 20). Blots were then incubated for 2 hr, at room temperature with either anti-PTEN or an antibody raised against the Ser 473 phosphorylated Akt (P-Akt) (Santa Cruz, Santa Cruz, CA). All primary antibodies were diluted 1:1000 in 3%
BSA. After the primary incubation, the blots were subjected to six 10-min washes and then incubated for 1 hr with the appropriate HRP-conjugated secondary antibody at a 1:5000 dilution. Blots were washed again, and visualized by enhanced chemiluminesence according to manufacturer's instruction. Germline DNA from the remaining 119 patients without deletions were sequenced for mutations in the 600-bp full promoter region of PTEN. Nine patients (9/119, 7.6%) were found to have heterozygous sequence variants within the PTEN promoter region (Fig. 3) . None of these promoter sequence variants were found among 186 normal Caucasian controls, suggesting that the former are likely pathogenic. Two other sequence variants (-903 G/A and -1026 C/A) were present in both patients and normal control individuals with similar allele frequencies (data not shown), suggesting that they were indeed polymorphisms.
Results
Using
To functionally assess the PTEN promoter point mutations, cellular protein was isolated from lymphoblastoid cells lines available from five cases with promoter mutations and subjected to Western blot analysis. Figure 4 shows that PTEN protein was recognized in control as well as case samples with promoter sequence variations.
Control samples and a sample from a PTEN mutation negative CS patient displayed a single immunoreactive protein of the correct size. Interestingly, samples from patients carrying the promoter mutations showed a decrease in immunoreactive PTEN of the correct molecular weight (Fig.4A , open arrowhead), concordant with a dramatic increase of a slightly lower immunoreactive band (Fig. 4A, closed arrowheads) . This lower band is visible in the PTEN mutation negative CS sample and in an occasional control, however, not to the same extent as the promotor mutation samples and never with a loss of immunoreactivity of PTEN. Three of the five promoter mutation positive cases had a laddering effect with several immunoreactive bands recognized at both lower and higher molecular weights (Fig. 4A, astericks) . We have analyzed 32
control samples and 23 PTEN mutation negative samples and have not observed this laddering effect (data not shown). These data strongly suggest that the lower molecular weight immunoreactive band and the laddering effect that we observe are specific and related to the promoter mutations in these patients. one of whom has CS. This is unusual as classic CS patients do not become symptomatic from hamartomatous polyps because these polyps are characteristically diminutive (Weber et al. 1998 ). While our patients' deletions are not cytogenetically obvious, at least three other unrelated CS or BRRS patients have been reported previously to have deletions or rearrangements in the PTEN region detected by cytogenetics (Arch et al. 1997; Tsuchiya et al. 1998; Marsh et al. 1999; Ahmed et al. 2000) . All three with cytogenetically detected PTEN deletion or rearrangements carried the clinical diagnosis of BRRS. Overall, therefore, at least five BRRS probands have been found to have deletions of or encompassing PTEN.
Until now, the PTEN promoter has not been examined in patients with CS and/or BRRS. However, in vitro work has shown that activated PPARγ, p53, and EGR1 have been shown to up-regulate PTEN transcription (Patel et al. 2001; Stambolic et al. 2001; Virolle et al. 2001) , suggesting that changes to the promoter sequence may indeed result in changes to PTEN protein structure, levels and function.
The genomic characterization of the PTEN promoter (Sheng et al. 2002) Of the nine patients with 10 promoter mutations (one case had two different sequence variants), five were localized to the minimum PTEN promoter region (-958 to -821), two of which (-920 G>T, -930 G>A) are predicted to alter two putative Sp1 transcription factor binding sites (Fig. 3) . Further, protein analysis revealed a reduced expression of wildtype PTEN, a strong lower molecular weight immunoreactive band, and a laddering effect of protein immunoreactive with a specific monoclonal antibody against human PTEN, suggesting that these point nucleotide substitutions are functionally significant and thus represent promoter mutations. These data suggest that the promoter variats may result in alternative start sites yielding PTEN protein of various sizes (Fig. 4A) . It is interesting to note that the two samples with mutations at the two putative Sp1 binding sites were the two with doublet PTEN immunoreactive bands but no laddering effect (Fig. 4A) . Although the transcriptional regulation of PTEN is only now beginning to be elucidated, we suspect that these variants would alter PTEN transcription resulting in impaired protein expression. The presence of some wildtype protein together with PTEN proteins of various sizes might be posulated to result in the milder phenotype associated with these promoter variants.
Another possibility is that the PTEN protein formed is also somehow altered at the protein level which results in targeted degradation, and it is the degradation of PTEN protein that we are observing. The mechanisms of PTEN degradation are only now being understood (Vazquez et al. 2000; Torres and Pulido 2001; Waite and Eng 2003) . Improper PTEN degradation could also result in impaired protein expression.
The precise mechanism for the appearance of the both the lower and higher molecular weight immunologically reactive PTEN species remains to be investigated.
Regardless of the mechanism of lower molecular weight proteins, we have demonstrated that the PTEN protein species produced in these promoter mutation positive patients is not active. The levels of phosphorylated-Akt were significantly higher in samples haboring promoter sequence variants compared to controls and PTEN mutation negative samples (Fig. 4B) , indicating an increase in the activity of the pro-proliferative PI3K/Akt pathway. 
